{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:34:45Z","timestamp":1793662485744,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05576-3","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:09:21Z","timestamp":1759759761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia, 2022\u20132023"],"prefix":"10.1186","volume":"24","author":[{"given":"Victor S.","family":"Koko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Skrip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odell","family":"Kumeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trokon","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou O.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kafuko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwem","family":"Inyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel F.","family":"Ponce de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika R.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro","family":"Zawolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birhanu","family":"Getahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahdae-mai","family":"Harmon-Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Plucinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"5576_CR1","first-page":"2024","volume-title":"addressing inequity in the global malaria response","author":"WHO. World malaria report","year":"2024","unstructured":"WHO. World malaria report. addressing inequity in the global malaria response. Geneva: World Health Organization; 2024. p. 2024."},{"key":"5576_CR2","volume-title":"Guidelines for malaria, 30 November 2024","author":"WHO","year":"2024","unstructured":"WHO. Guidelines for malaria, 30 November 2024. Geneva.: World Health Organization; 2024."},{"key":"5576_CR3","volume-title":"Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide","author":"WHO","year":"2024","unstructured":"WHO. Multiple first-line therapies as part of the response to antimalarial drug resistance: an implementation guide. Geneva: World Health Organization; 2024."},{"key":"5576_CR4","volume-title":"Global technical strategy for malaria 2016\u20132030, 2021 update","author":"WHO","year":"2021","unstructured":"WHO. Global technical strategy for malaria 2016\u20132030, 2021 update. Geneva: World Health Organization; 2021."},{"key":"5576_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1186\/s12879-024-09912-x","volume":"24","author":"F Camponovo","year":"2024","unstructured":"Camponovo F, Jeandron A, Skrip LA, Golumbeanu M, Champagne C, Symons TL, et al. Malaria treatment for prevention: a modelling study of the impact of routine case management on malaria prevalence and burden. BMC Infect Dis. 2024;24:1267.","journal-title":"BMC Infect Dis"},{"key":"5576_CR6","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","author":"WHO","year":"2020","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva: World Health Organization; 2020."},{"key":"5576_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taad159","volume":"30","author":"ES Halsey","year":"2023","unstructured":"Halsey ES, Plucinski MM. Out of Africa: increasing reports of artemether-lumefantrine treatment failures of uncomplicated Plasmodium falciparum infection. J Travel Med. 2023;30:taad159.","journal-title":"J Travel Med"},{"key":"5576_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5576_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad MD, Asua V, Garg S, Giesbrecht D, Niare K, Smith S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389:722\u201332.","journal-title":"N Engl J Med"},{"key":"5576_CR10","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S1473-3099(19)30261-0","volume":"19","author":"MD Conrad","year":"2019","unstructured":"Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019;19:e338\u201351.","journal-title":"Lancet Infect Dis"},{"key":"5576_CR11","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"5576_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12936-024-04896-0","volume":"23","author":"C Bakari","year":"2024","unstructured":"Bakari C, Mandara CI, Madebe RA, Seth MD, Ngasala B, Kamugisha E, et al. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021. Malar J. 2024;23:71.","journal-title":"Malar J"},{"key":"5576_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5576_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12936-020-03290-w","volume":"19","author":"AH Beavogui","year":"2020","unstructured":"Beavogui AH, Camara A, Delamou A, Diallo MS, Doumbouya A, Kourouma K, et al. Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial. Malar J. 2020;19:223.","journal-title":"Malar J"},{"key":"5576_CR15","first-page":"49","volume":"64","author":"A Konate","year":"2018","unstructured":"Konate A, Barro-Kiki PCM, Angora KE, Bedia-Tanoh AV, Djohan V, Kassi KF, et al. Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across Cote d\u2019Ivore. Ann Parasitol. 2018;64:49\u201357.","journal-title":"Ann Parasitol"},{"key":"5576_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.actatropica.2018.06.016","volume":"185","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, Kamara ARY, Sahr F, Samai M, Swaray AS, Menard D, et al. Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Acta Trop. 2018;185:363\u201370.","journal-title":"Acta Trop"},{"key":"5576_CR17","volume":"2015","author":"W Yavo","year":"2015","unstructured":"Yavo W, Konate A, Kassi FK, Djohan V, Angora EK, Kiki-Barro PC, et al. Efficacy and safety of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sentinel sites across Cote d\u2019Ivoire. Malar Res Treat. 2015;2015:878132.","journal-title":"Malar Res Treat"},{"key":"5576_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Ringwald P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar J. 2021;20:320.","journal-title":"Malar J"},{"key":"5576_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12936-024-04923-0","volume":"23","author":"B Ngasala","year":"2024","unstructured":"Ngasala B, Bushukatale S, Chiduo M, Makene T, Mkony L, Mohamed A, et al. Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania. Malar J. 2024;23:90.","journal-title":"Malar J"},{"key":"5576_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/infdis\/jiae425","volume":"231","author":"JE Laury","year":"2025","unstructured":"Laury JE, Mugittu K, Kajeguka DC, Kamugisha E, Ishengoma DS, Mandara CI, et al. Efficacy and safety of artemether-lumefantrine against uncomplicated falciparum malaria infection in Tanzania, 2022: a single-arm clinical trial. J Infect Dis. 2025;231:251\u20139.","journal-title":"J Infect Dis"},{"key":"5576_CR21","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5576_CR22","unstructured":"Liberia Malaria Indicator Survey 2022. Monrovia, Liberia, and Rockville, Maryland, USA: NMCP and ICF; 2023."},{"key":"5576_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-251","volume":"12","author":"B Schramm","year":"2013","unstructured":"Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malar J. 2013;12:251.","journal-title":"Malar J"},{"issue":"1","key":"5576_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04140-7","volume":"21","author":"VS Koko","year":"2022","unstructured":"Koko VS, Warsame M, Vonhm B, Jeuronlon MK, Menard D, Ma L, et al. Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. Malar J. 2022;21(1):134.","journal-title":"Malar J"},{"key":"5576_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0264339.","journal-title":"PLoS ONE"},{"key":"5576_CR26","volume-title":"Malaria National Strategic Plan 2021\u20132025","author":"National Malaria Control Programme","year":"2020","unstructured":"National Malaria Control Programme. Malaria National Strategic Plan 2021\u20132025. Liberia: Ministry of Health; 2020."},{"key":"5576_CR27","volume-title":"Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas","author":"WHO","year":"2021","unstructured":"WHO. Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas. Geneva: World Health Organization; 2021."},{"key":"5576_CR28","unstructured":"Efficacy of artesunate-amodiaquine and artemether-lumefantrine for treatment of Plasmodium falciparum malaria in Liberia. 2022. https:\/\/clinicaltrials.gov\/study\/NCT06300970."},{"key":"5576_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00228-007-0452-8","volume":"64","author":"C Orrell","year":"2008","unstructured":"Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, et al. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol. 2008;64:683\u201390.","journal-title":"Eur J Clin Pharmacol"},{"key":"5576_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12936-020-03553-6","volume":"20","author":"TA Anyorigiya","year":"2021","unstructured":"Anyorigiya TA, Castel S, Mauff K, Atuguba F, Ogutu B, Oduro A, et al. Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malar J. 2021;20:18.","journal-title":"Malar J"},{"key":"5576_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37:105\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"5576_CR32","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimde","year":"2009","unstructured":"Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J. 2009;8(Suppl 1):S4.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05576-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:09:24Z","timestamp":1759759764000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05576-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5576"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05576-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study protocol was obtained from the University of Liberia Pacific Institute for Research and Evaluation (UL-PIRE) Institutional Review Board (ULIRB) and was determined as non-research activity within the U.S. Centers for Disease Control and Prevention (CDC) (0900f3eb81e634a9). The study was registered on the US NIH Clinical Trials website (ClinicalTrials.gov ID NCT06300970). Parents\/guardians were informed of the study procedure, its benefits, potential risks, and gave written informed consent for their children to participate in the study prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors consent for the publication of the included results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}